Remedy for integration dysfunction syndrome
AssigneeSumitomo Dainippon Pharma Co., Ltd.
InventorsMitsutaka Nakamura, Masaaki Ogasa, Shunsuke Sami
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)—N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily dose of 5 mg to 120 mg once a day to a patient with schizophrenia, and a therapeutic agent to be used in the method.
Claims11
A method for treating the negative symptoms of schizophrenia and/or the cognitive dysfunction of schizophrenia in a patient, which comprises orally administering a once daily dose of 5 mg to 120 mg of the active compound:
- (1R,2S,3R,4S)—N[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide of the formula (1):
- or a pharmaceutically acceptable salt thereof to a patient suffering from negative symptoms of schizophrenia and/or cognitive dysfunction of schizophrenia.
Dependencies are inferred from the claim text.